Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077917 · ClinicalTrials.gov registry record · Phase 3
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
A Phase 3 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT05077917: Clinical Trial Phase 3 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
NCT05077917 is a Phase 3 study that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 22 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05077917, a Phase 3 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life. Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn will be administered as a nebulized treatment four times a day for four days followed by intranasal administration for two weeks. Investigators may also screen for biomarkers that could indicate inflammatory responses and treatment-induced improvement. Participants will receive either study drug or placebo which will be administered by nebulization for 4 days followed by 14 days of intranasal administration. Participants will be followed while in the hospital and then as outpatients up to day 21 following randomization.
Primary Outcome
Determination of trend in subject's need for oxygen supplementation over time.
Interventions
- OTHER Placebo
- DRUG Cromolyn Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 3 |
Why NCT05077917 stopped before completion
NCT05077917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05077917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05077917 about?
NCT05077917 is a clinical study titled "Cromolyn Sodium for Treatment of COVID-19 Pneumonia". The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life. Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pn...
What is the current status of trial NCT05077917?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2021-11-15. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05077917?
The interventions under investigation include: Placebo (OTHER), Cromolyn Sodium (DRUG).
Who is sponsoring clinical trial NCT05077917?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05077917's enrollment target sits among peer trials
22 1953rd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI